Investigators at The Feinstein Institute for Medical Research discovered dozens of new genetic variations associated with a person’s general cognitive ability. The findings, which were published online today in Cell Reports, have the potential to help researchers develop more targeted treatment for cognitive and memory disorders.
A recent study analyzed population-based data to determine the global causes of blindness and visual impairment and made projections by cause to 2020.
French startup Doctolib is raising money for the second time in the past twelve months. The company is building a sort of Salesforce for the healthcare industry with a big emphasis on bookings. Doctolib just raised $42 million (€35 million) from Eurazeo and existing investor Bpifrance.
Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).
Review Designation of Mogamulizumab’s Biologics License Application
First, it's important to remember why you’re on antibiotics to begin with: You feel awful and, with some help from your prescription, your body is working to fight off a nasty bacterial infection. (Antibiotics cannot treat anything viral, like a flu.)
It may be possible to use drugs that are already in development to overcome radiotherapy resistance in tumors, which is often a major barrier to the successful treatment of many cancers.
A study reviews data on the indications for use of antipsychotics in elderly patients with dementia across four clinical settings in Canada.
While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine shows that the virus kills brain cancer stem cells, the kind of cells most resistant to standard treatments.
Medeor Therapeutics announced it had closed on an oversubscribed Series B financing worth $57 million. The round was led by RA Capital Management. New investors included Sofinnova Ventures and 6 Dimensions Capital. They were joined by existing investors Vivo Capital and WuXi Healthcare Ventures.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.